{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:50:44Z","timestamp":1786121444089,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020154","name":"Protagonist Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clml.2026.05.006","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T23:40:49Z","timestamp":1779493249000},"page":"549-561.e23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7415","authenticated-orcid":false,"given":"Andrew T.","family":"Kuykendall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0161-5775","authenticated-orcid":false,"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Reaven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Funk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Oyuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Valone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Bellamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7813-9940","authenticated-orcid":false,"given":"Suneel","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clml.2026.05.006_bib0001","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and treatment of polycythemia vera: a review","volume":"333","author":"Tremblay","year":"2025","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clml.2026.05.006_bib0002","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11864-018-0529-x","article-title":"Polycythemia vera","volume":"19","author":"Spivak","year":"2018","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"10.1016\/j.clml.2026.05.006_bib0003","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.05.006_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-016-0031-8","article-title":"Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review","volume":"5","author":"Parasuraman","year":"2016","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.006_bib0005","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.05.006_bib0006","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2026.05.006_bib0007","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/biomedicines11071925","article-title":"Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: the Polycythemia Vera-Advanced Integrated Models (PV-AIM) project","volume":"11","author":"Verstovsek","year":"2023","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.clml.2026.05.006_bib0008","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00277-023-05089-6","article-title":"Real-world treatments and thrombotic events in polycythemia vera patients in the USA","volume":"102","author":"Verstovsek","year":"2023","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.05.006_bib0009","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2147\/VHRM.S429995","article-title":"Diagnosis and management of cardiovascular risk in patients with polycythemia vera","volume":"19","author":"Benevolo","year":"2023","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clml.2026.05.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106667","article-title":"Autoimmune disorders and the risk of thrombotic events in polycythaemia vera","volume":"110","author":"Kre\u010dak","year":"2021","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.clml.2026.05.006_bib0011","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.mayocp.2018.08.022","article-title":"3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups","volume":"94","author":"Szuber","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.clml.2026.05.006_bib0012","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2026.05.006_bib0013","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","article-title":"Thromboembolic events in polycythemia vera","volume":"98","author":"Griesshammer","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.05.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106809","article-title":"Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia","volume":"115","author":"Pemmaraju","year":"2022","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.clml.2026.05.006_bib0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3324\/haematol.2019.221234","article-title":"Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis","volume":"104","author":"Ferrari","year":"2019","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2026.05.006_bib0016","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"issue":"22","key":"10.1016\/j.clml.2026.05.006_bib0017","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2026.05.006_bib0018","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2026.05.006_bib0019","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.006_bib0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11739-009-0319-3","article-title":"Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia","volume":"5","author":"Vannucchi","year":"2010","journal-title":"Intern Emerg Med"},{"issue":"1","key":"10.1016\/j.clml.2026.05.006_bib0021","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41408-024-01169-6","article-title":"Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors","volume":"14","author":"Barbui","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.05.006_bib0022","first-page":"47","article-title":"Health care costs and thromboembolic events in hydroxyurea-treated patients with polycythemia vera","volume":"24","author":"Parasuraman","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.clml.2026.05.006_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26362","article-title":"Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001-2017","volume":"96","author":"Dores","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.05.006_bib0024","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00277-022-04826-7","article-title":"Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions","volume":"101","author":"Goulart","year":"2022","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.clml.2026.05.006_bib0025","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00277-019-03793-w","article-title":"Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data","volume":"98","author":"Parasuraman","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.05.006_bib0026","unstructured":"Market Clarity: Linked EHR and Claims Data. Available at: https:\/\/business.optum.com\/en\/data-analytics\/life-sciences\/real-world-data\/market-clarity-data.html. Accessed: January 9, 2025."},{"issue":"12","key":"10.1016\/j.clml.2026.05.006_bib0027","doi-asserted-by":"crossref","first-page":"929","DOI":"10.7326\/0003-4819-141-12-200412210-00009","article-title":"Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease","volume":"141","author":"Rule","year":"2004","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.clml.2026.05.006_bib0028","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2015-04-638593","article-title":"White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study","volume":"126","author":"Barbui","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2026.05.006_bib0029","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","article-title":"Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients","volume":"7","author":"Cerquozzi","year":"2017","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1016\/j.clml.2026.05.006_bib0030","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2023020232","article-title":"Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL","volume":"143","author":"Gerds","year":"2024","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.clml.2026.05.006_bib0031","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.clml.2026.05.006_bib0032","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3324\/haematol.12053","article-title":"Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments","volume":"93","author":"De Stefano","year":"2008","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2026.05.006_bib0033","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.05.006_bib0034","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/bjh.19337","article-title":"Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera\u2014a matched nationwide population-based study","volume":"204","author":"Enblom-Larsson","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.006_bib0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/03007995.2024.2438996","article-title":"Characteristics, blood counts, treatments, and clinical outcomes of 5871 patients with polycythemia vera treated in US community practices","volume":"41","author":"Lyons","year":"2025","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.clml.2026.05.006_bib0036","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.05.006_bib0037","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.21593","article-title":"Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia","volume":"85","author":"De Stefano","year":"2010","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.05.006_bib0038","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.clml.2019.11.010","article-title":"Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: a real-world analysis of Veterans Health Administration data","volume":"20","author":"Parasuraman","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 2","key":"10.1016\/j.clml.2026.05.006_bib0039","first-page":"S43","article-title":"Hematocrit, white blood cells, and thrombotic events in the veteran population with polycythemia vera","volume":"39","author":"Tashi","year":"2022","journal-title":"Fed Pract"},{"issue":"11","key":"10.1016\/j.clml.2026.05.006_bib0040","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/bloodadvances.2019000211","article-title":"Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis","volume":"3","author":"Carobbio","year":"2019","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.clml.2026.05.006_bib0041","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood.2019003347","article-title":"Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis","volume":"135","author":"Ronner","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.05.006_bib0042","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-022-00625-5","article-title":"Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera","volume":"12","author":"Carobbio","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.05.006_bib0043","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41408-024-01176-7","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in polycythemia vera: insights from a prospective cohort analysis","volume":"14","author":"Barbui","year":"2024","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2026.05.006_bib0044","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1007\/s00277-024-05898-3","article-title":"Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis","volume":"103","author":"Nagaharu","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.006_bib0045","first-page":"347","article-title":"Prevalence, incidence, and thromboembolic events in polycythemia vera: a study based on longitudinal German health claims data","volume":"104","author":"Manz","year":"2025","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.clml.2026.05.006_bib0046","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/17474086.2025.2538542","article-title":"An observational study of disease management in adult patients with polycythemia vera: results from a large U.S. claims database","volume":"18","author":"Kuykendall","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2026.05.006_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-142549","article-title":"Real-world treatments and thrombotic events in polycythemia vera patients: a retrospective analysis between 2018 and 2019 in US population","volume":"136","author":"Verstovsek","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:01:58Z","timestamp":1786078918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2152265026001473"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Thromboembolic Events in Patients With Polycythemia Vera: A Real-World Observational Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}